can you still get semaglutide compounded for Women Despite FDA ruling, compounded GLP-1s

It's important to note that none of these improve outcomes, and niacin in particular worsens outcomes and insulin resistance, see the niacin article

Following the success of the SELECT trial, Wegovy (semaglutide in doses of 1.7 mg and 2.4 mg) received a similar approval in March 2024 for people with overweight or obesity and cardiovascular disease

Using GLP-1 RAs in conjunction with other glucose-lowering or cardiovascular medications can significantly enhance treatment effectiveness, reduce side effects, and better meet the diverse needs of different patients

If your appetite shifts, weight loss stalls or side effects show up, adjustments may be needed